$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

$uncy Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024042298 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue			$675.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.533M	$2.391M	$62.00K
YoY Change	1212.44%	3756.45%	-96.13%
% of Gross Profit
Research & Development	$4.868M	$6.813M	$3.030M
YoY Change	114.73%	124.85%	56.75%
% of Gross Profit
Depreciation & Amortization	$0.00	$9.000K	$2.000K
YoY Change	-100.0%	350.0%	0.0%
% of Gross Profit
Operating Expenses	$7.401M	$9.204M	$4.877M
YoY Change	71.24%	88.72%	37.89%
Operating Profit	-$7.401M	-$9.204M	-$4.202M
YoY Change	71.24%	119.04%
Interest Expense	$446.0K	$20.00K	$12.00K
YoY Change	1293.75%	66.67%
% of Operating Profit
Other Income/Expense, Net	$17.26M	-$11.76M	-$10.38M
YoY Change	6019.15%	13.34%
Pretax Income	$9.855M	-$20.96M	-$14.58M
YoY Change	-356.77%	43.83%	312.07%
Income Tax
% Of Pretax Income
Net Earnings	$9.855M	-$20.96M	-$14.58M
YoY Change	-356.77%	43.83%	312.07%
Net Earnings / Revenue			-2159.26%
Basic Earnings Per Share	$0.08	-$0.61	-$0.97
Diluted Earnings Per Share	-$0.15	-$0.61	-$0.97
COMMON SHARES
Basic Shares Outstanding	37.61M shares	34.76M shares	15.23M shares
Diluted Shares Outstanding	94.05M shares	34.91M shares	15.23M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.78M	$48.93M	$24.33M
YoY Change	122.02%	101.09%	78.65%
Cash & Equivalents	$41.78M	$48.93M	$24.33M
Short-Term Investments
Other Short-Term Assets	$2.274M	$2.746M	$1.852M
YoY Change	-26.93%	48.27%	0.43%
Inventory			$1.852M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$44.05M	$51.68M	$26.18M
YoY Change	100.88%	97.36%	69.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$43.00K	$23.00K	$21.00K
YoY Change	43.33%	9.52%	-92.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$647.0K	$709.0K	$1.018M
YoY Change	-32.11%	-30.35%	243.92%
TOTAL ASSETS
Total Short-Term Assets	$44.05M	$51.68M	$26.18M
Total Long-Term Assets	$647.0K	$709.0K	$1.018M
Total Assets	$44.70M	$52.39M	$27.20M
YoY Change	95.35%	92.58%	72.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.472M	$1.240M	$790.0K
YoY Change	192.64%	56.96%	34.13%
Accrued Expenses	$3.122M	$3.550M	$1.698M
YoY Change	84.84%	109.07%	-6.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.09M	$30.28M	$15.97M
YoY Change	-15.13%	89.62%	564.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$274.0K	$372.0K	$715.0K
YoY Change	-56.78%	-47.97%	527.19%
Total Long-Term Liabilities	$274.0K	$372.0K	$715.0K
YoY Change	-56.78%	-47.97%	527.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.09M	$30.28M	$15.97M
Total Long-Term Liabilities	$274.0K	$372.0K	$715.0K
Total Liabilities	$13.36M	$30.65M	$16.69M
YoY Change	-16.78%	83.72%	563.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.60M	-$85.50M	-$48.57M
YoY Change	44.25%	76.03%
Common Stock	$43.00K	$37.00K	$15.00K
YoY Change	186.67%	146.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$14.85M	-$24.46M	-$15.08M
YoY Change
Total Liabilities & Shareholders Equity	$44.70M	$52.39M	$27.20M
YoY Change	95.35%	92.58%	72.6%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$9.855M	-$20.96M	-$14.58M
YoY Change	-356.77%	43.83%	312.07%
Depreciation, Depletion And Amortization	$0.00	$9.000K	$2.000K
YoY Change	-100.0%	350.0%	0.0%
Cash From Operating Activities	-$6.319M	-$6.456M	-$3.920M
YoY Change	14.85%	64.69%	32.57%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$6.000K
YoY Change	66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$20.00K	-$6.000K
YoY Change	66.67%
FINANCING ACTIVITIES
Cash Dividend Paid			$200.0K
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-811.0K	$45.69M	$27.80M
YoY Change		64.37%
NET CHANGE
Cash From Operating Activities	-6.319M	-$6.456M	-$3.920M
Cash From Investing Activities	-20.00K	-$6.000K
Cash From Financing Activities	-811.0K	$45.69M	$27.80M
Net Change In Cash	-7.150M	$39.23M	$23.88M
YoY Change	29.67%	64.3%
FREE CASH FLOW
Cash From Operating Activities	-$6.319M	-$6.456M	-$3.920M
Capital Expenditures	$20.00K	$6.000K
Free Cash Flow	-$6.339M	-$6.462M	-$3.920M
YoY Change	14.96%	64.85%	32.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15232406	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34912692	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34912692	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q1	uncy	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40582
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	UNICYCIVE THERAPEUTICS, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3638692
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4300 El Camino Real
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Altos
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94022
CY2024Q1	dei	City Area Code CityAreaCode	(650)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	351-4495
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	UNCY
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37606630	shares
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9701000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48930000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3698000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2746000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	13399000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	51676000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	766000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	686000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23000	usd
CY2023Q4	us-gaap	Assets Assets	14191000	usd
CY2024Q1	us-gaap	Assets Assets	52385000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	839000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1240000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3234000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3550000	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	208000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13134000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	24941000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	327000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	343000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17534000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	30282000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	466000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	372000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	18000000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	30654000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9926161	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9904773	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34756049	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34756049	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37606630	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37606630	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	35000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	37000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60697000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61011000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64541000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85504000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3809000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-24456000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14191000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52385000	usd
CY2023Q1	us-gaap	Revenues Revenues	675000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3030000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6813000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1847000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2391000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4877000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	9204000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4202000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9204000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	69000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	12000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	20000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10375000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11808000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10373000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11759000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14575000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20963000	usd
CY2024Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	208000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14767000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21171000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.97
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15232406	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34912692	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14575000	usd
CY2023Q1	uncy	Stock Issued During Period Value Deemed Dividends On Series A1 Preferred Stock StockIssuedDuringPeriodValueDeemedDividendsOnSeriesA1PreferredStock	-192000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	144000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-15082000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3809000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20963000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	208000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	522000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-24456000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14575000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20963000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	9000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	144000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	522000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10375000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11808000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	43000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	275000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-338000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1344000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-193000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	822000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-54000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-273000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3920000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6456000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	240000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	496000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-3813000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	50000000	usd
CY2023Q1	uncy	Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr	2153000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	30190000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27797000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45691000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	23877000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	39229000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	455000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9701000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24332000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48930000	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	192000	usd
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	208000	usd
CY2023Q1	uncy	Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock	2831000	usd
CY2024Q1	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	146000	usd
CY2023Q1	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	121000	usd
CY2024Q1	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	86000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	5000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64500000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Other Receivables ProceedsFromSaleOfOtherReceivables	46200000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract progress estimates, and the fair value of warrant liabilities. Actual results may materially differ from those estimates.</p>
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	24941000	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	24941000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13134000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	13134000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10400000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11800000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are held in accounts at various financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through March 31, 2024.</p>
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.50	pure
CY2024Q1	uncy	Payment Of Vender Net Revenue PaymentOfVenderNetRevenue	2000000	usd
CY2024Q1	uncy	Vendor Payment VendorPayment	2000000	usd
CY2024Q1	uncy	Consecutive Year ConsecutiveYear	P4Y
CY2024Q1	uncy	Total Payments Of Commercial Supplies TotalPaymentsOfCommercialSupplies	10000000	usd
CY2017Q4	uncy	Agreement Due Payments AgreementDuePayments	50000	usd
CY2017Q4	uncy	Second Clinical Trial Payment SecondClinicalTrialPayment	50000	usd
CY2017Q4	uncy	Royalty Pecentage RoyaltyPecentage	0.02	pure
CY2021Q3	us-gaap	Capitalization Longterm Debt And Equity CapitalizationLongtermDebtAndEquity	50000000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2200000	usd
CY2024Q1	uncy	Sublicense Income Percentage SublicenseIncomePercentage	0.40	pure
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2000000	usd
CY2022Q1	uncy	Revisions Reduced The Overall Budget RevisionsReducedTheOverallBudget	2900000	usd
CY2023Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	100000	usd
CY2023Q1	uncy	Milestone Payments MilestonePayments	3700000	usd
CY2024Q1	uncy	Total Payments TotalPayments	3700000	usd
CY2024Q1	us-gaap	Debt And Equity Securities And Foreign Currency Transaction Price Change Unrealized Gain Loss Operating Before Tax DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax	675000000	usd
CY2024Q1	uncy	Transaction Price TransactionPrice	675000000	usd
CY2023Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	675000000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	270000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	146000	usd
CY2023Q4	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	3103000	usd
CY2024Q1	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	2097000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	325000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	503000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3698000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2746000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	21000	usd
CY2024Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	21000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	21000	usd
CY2024Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	21000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	42000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	42000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	821000	usd
CY2024Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1171000	usd
CY2023Q4	uncy	Credit Card Liability CreditCardLiability	18000	usd
CY2024Q1	uncy	Credit Card Liability CreditCardLiability	69000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	839000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1240000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1917000	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1965000	usd
CY2023Q4	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	1034000	usd
CY2024Q1	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	1336000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	283000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	250000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3234000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3550000	usd
CY2021Q4	us-gaap	Area Of Land AreaOfLand	2367	sqft
CY2024Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2023Q1	us-gaap	Area Of Land AreaOfLand	2456	sqft
CY2024Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	three additional years
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.10	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	294000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	424000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	72000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	790000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	715000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	343000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	372000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	210000	usd
CY2021Q4	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1	pure
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	107000	usd
CY2024Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	35000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Share Price SharePrice	5
CY2024Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	736773	shares
CY2024Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	184193	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4784193	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	6
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y6M14D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4784193	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	6
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y3M14D
CY2024Q1	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	(i) shares of common stock of the Company and, if applicable, shares of Series A-2 Preferred Stock, in lieu of common stock, (ii) a tranche A warrant to acquire approximately 46,675,940 shares (excluding deemed dividends) of Series A-3 Preferred Stock (the “Tranche A Warrant”), (iii) a tranche B warrant to acquire approximately 42,432,672 shares (excluding deemed dividends) of Series A-4 Preferred Stock (the “Tranche B Warrant”), and (iv) a tranche C warrant to acquire approximately 67,892,276 shares (excluding deemed dividends) of Series A-5 Preferred Stock (the “Tranche C Warrant”, together with the Tranche A Warrant and the Tranche B Warrant, the “Warrants”). The Tranche A Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Company’s announcement of receipt of FDA approval for Oxylanthanum Carbonate, the Tranche B Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Company’s announcement of receipt of Transitional Drug Add-On Payment Adjustment (“TDAPA”) approval for Oxylanthanum Carbonate, and the Tranche C Warrant for an aggregate exercise price of approximately $50 million is exercisable until 21 days following four quarters of commercial sales of Oxylanthanum Carbonate following receipt of TDAPA approval.
CY2024Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2800000	usd
CY2024Q1	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	25400000	usd
CY2023Q3	us-gaap	Shares Issued SharesIssued	19516205	shares
CY2023Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	43649	shares
CY2024Q1	us-gaap	Dividends Common Stock DividendsCommonStock	1000	usd
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2024Q1	us-gaap	Proceeds From Sale Of Other Receivables ProceedsFromSaleOfOtherReceivables	46200000	usd
CY2024Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.14	pure
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2024Q1	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	one
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.199	pure
CY2024Q1	us-gaap	Extended Product Warranty Description ExtendedProductWarrantyDescription	the fair value of the Warrants was determined using a Black Scholes model using parameters including (i) the exercise price of the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, and (vi) estimated probability assumptions surrounding the achievement by the Company of technical milestones associated with regulatory and commercial progress.
CY2023Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	2800000	usd
CY2023	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	13100000	usd
CY2024Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	24900000	usd
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1302326	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	12775996	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2815503	shares
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2796503	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10302086	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M2D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1196000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	19000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.83
CY2024Q1	uncy	Share Based Compensation Arrangementby Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y9M25D
CY2024Q1	uncy	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue	10000	usd
CY2024Q1	uncy	Stock Issued During Period Shares Stock Option Exercised StockIssuedDuringPeriodSharesStockOptionExercised	581	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.27
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10320505	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M2D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6006000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3038175	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.45
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y6M29D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1516000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	4500000	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P2Y9M18D
CY2023Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	10000	shares
CY2023Q3	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	7500	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.75
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3000	usd
CY2021	uncy	Exercised Stock Option ExercisedStockOption	383721	shares
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	119000	usd
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	776	shares
CY2024Q1	uncy	Unvested Options Amount UnvestedOptionsAmount	2500	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1900	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	382939	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	10000	shares
CY2022Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	7200	usd
CY2022Q2	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	0.72
CY2024Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	800	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	144000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	522000	usd
CY2024Q1	uncy	Annual Net Cash Flow From Operations Percentage AnnualNetCashFlowFromOperationsPercentage	0.75	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0648	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0405	pure
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14575000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20963000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	192000	usd
CY2024Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	208000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14767000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21171000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15232406	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34912692	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.97
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	163121570	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	176062865	shares
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.97
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2024Q1	uncy	Stock Issued During Period Value Issuance Of Series B1 Preferred Stock Net Of Issuance Costs StockIssuedDuringPeriodValueIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2024Q1	uncy	Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants		usd
CY2024Q1	uncy	Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock		usd
CY2023Q1	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85500000	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
CY2024Q1	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsGranted
CY2024Q1	uncy	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Granted SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsGranted		usd
CY2024Q1	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod		shares
CY2024Q1	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodIntrinsicValue
CY2024Q1	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsExercised
CY2024Q1	uncy	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsExercised		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	uncy	Weighted Average Remaining Contractual Termin Years Options Forfeited WeightedAverageRemainingContractualTerminYearsOptionsForfeited
CY2024Q1	uncy	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14767000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21171000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15232406	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.97
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001766140

Files In Submission

Name	View Source	Status
0001213900-24-042298-index-headers.html	Edgar Link	pending
0001213900-24-042298-index.html	Edgar Link	pending
0001213900-24-042298.txt	Edgar Link	pending
0001213900-24-042298-xbrl.zip	Edgar Link	pending
ea0205291-10q_unicycive.htm	Edgar Link	pending
ea020529101ex31-1_unicycive.htm	Edgar Link	pending
ea020529101ex31-2_unicycive.htm	Edgar Link	pending
ea020529101ex32-1_unicycive.htm	Edgar Link	pending
ea020529101ex32-2_unicycive.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
ea0205291-10q_unicycive_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uncy-20240331.xsd	Edgar Link	pending
uncy-20240331_def.xml	Edgar Link	unprocessable
uncy-20240331_lab.xml	Edgar Link	unprocessable
uncy-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
uncy-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

2024 Q2 Form 10-Q Financial Statement

#000121390024042298 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY Unicycive Therapeutics, Inc. Stock $uncy

2024 Q2 Form 10-Q Financial Statement

#000121390024042298 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy